Golden Biotechnology Corp. a Taiwanese biopharmaceutical company, announced that its Phase 2 COVID-19 trial for oral new drug Antroquinonol (HOCENA®) has achieved 100% recovery results of its primary outcome measure in hospitalized mild, moderate including ICU severe patients. - Click here if this is your press release! - eTurboNews | Trends | Travel News